Recruiting

Omegaven

Sponsor:

Carle Foundation Hospital

Code:

NCT02334293

Conditions

Cholestasis

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

Omegaven

Study Details

Brief summary:

The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.

Conditions

Cholestasis

Study ID

NCT02334293

Start date

Oct, 2013

Status verified date

Jan, 2015

Primary completion date

Jul, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Greater than 14 days old.
  • Have PN-associated cholestasis defined as at least 2 consecutive direct bilirubin >2 mg/dL with anatomical or functional short gut (OR >4 mg/dL if intact intestine) obtained at least 1 week apart with a ratio of direct: total bilirubin > 0.4.
  • Patients will be PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least 4 more weeks.
  • Patients must have failed standard therapies for Parenteral Nutrition Associated Liver Disease (PNALD) including: cycling of PN, avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding, and use of ursodiol (i.e. Actigall).
  • Signed patient informed consent.
  • The patient is expected to have a reasonable possibility of survival.
  • No other known etiology of cholestasis other than PNALD at time of Omegaven® initiation.

Exclusion Criteria:

  • Causes of cholestasis other than PNALD including but not limited to Hepatitis C, Cystic fibrosis, biliary atresia, and alpha 1 anti-trypsin deficiency, prior to Omegaven® initiation.
  • Known fish or egg allergy
  • Any of the contraindications to use of Omegaven®:

1. Active new infection at the time of initiation of Omegaven®
2. Hemodynamic instability
3. Use of medications with associated risk of bleeding, including nonsteroidal antiinflammatory drugs (NSAIDs)
4. Active coagulopathy or bleeding
5. Thrombocytopenia
6. Unstable hyperglycemia
7. Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1 g/kg/day or less of Intralipid
8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.)
9. Unstable diabetes mellitus
10. Collapse and shock
11. Stroke/ Embolism
12. Cardiac infarction within the last 3 months
13. Undefined coma status
  • Enrollment in a clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team)
  • The parent or guardian of child is unwilling to provide consent or assent

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Omegaven

Interventions

Omegaven

Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.

Primary outcome measure

  • Primary Outcomes/Endpoints ( time from baseline until the patient normalizes bilirubin (presents three consecutive direct bilirubin ≤ 2 mg/dL or a direct bilirubin ≤ 2 mg/dL and weaned from PN) [ Time Frame: Until weaned from PN ]

Central Contacts and Locations

Locations

Carle Foundation Hospital

Recruiting

Urbana, Illinois, United States, 61801

Contacts

Principal Investigator:

William Stratton, MD

More Information

Sponsor

Carle Foundation Hospital

Last update posted

Jan 8, 2015

Last verified

Jan, 2015

Keywords

  • Omegaven
  • parenteral nutrition
  • liver disease
  • liver injury

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Carle Foundation Hospital on 2015-01-08.